Exelixis (EXEL)
(Real Time Quote from BATS)
$20.48 USD
-0.09 (-0.44%)
Updated May 28, 2024 11:48 AM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Brokerage Reports
0 items in cart
Exelixis, Inc. [EXEL]
Reports for Purchase
Showing records 41 - 60 ( 178 total )
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Surprise, It?s No Surprise: EXEL Decides Not to File sNDA for Cabo in 1L HCC After All
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Steady Growth of Cabo-Nivo in 2021; Greater Visibility for XL092 in 2022; Reiterate Buy and Reduce PT to $42 From $52
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Cabo-Nivo Combo in RCC Continues to Improve Survival and Quality of Life at 2-Year Follow-Up; Reiterate Buy and $52 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Promising CAMILLA and COSMIC-021 Trial Data in CRC to be Presented at ASCO GI; Reiterate Buy and $52 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Exelixis Unveils Preliminary 2021 Financial Results and Provides 2022 Guidance; Reiterate Buy and $52 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Phase 3 Trial, CONTACT-03, Concludes Enrollment in RCC; Reiterate Buy and $52 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Cabo Successor XL092 Enters Broad Clinical Development Program With Ipi/Nivo +/- Bempeg; Reiterate Buy and $52 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
COSMIC 312 Data in 1L HCC Presented at ESMO Asia; XL092 Will Likely Carry the Torch; Reiterate Buy and $52 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M